Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yutaka Yoshida is active.

Publication


Featured researches published by Yutaka Yoshida.


World journal of clinical oncology | 2011

Expected clinical applications of circulating tumor cells in breast cancer

Youngjin Park; Tomoaki Kitahara; Tasuku Urita; Yutaka Yoshida; Ryoji Kato

Tumor cell invasion and intravascular filtration lead to the presence of circulating tumor cells (CTCs) in peripheral blood. CTCs have, thus, been counted in patients with cancer to analyze metastatic mechanisms or in the hope of developing clinical applications for diagnosis and therapy; various CTC-related studies have been performed. However, the clinical significance of CTCs remains to be established because of the extremely small number of CTCs in peripheral blood as compared with the number of blood cells. Technical problems (e.g. reproducibility and reliability) in the detection of CTCs also remain to be solved. The use of flow cytometric analysis, which can be performed with tumor-cell markers such as anti-epithelial cell adhesion molecule antibodies and anti-cytokeratin antibodies and non-tumor-cell markers such as anti-CD45 antibodies has enhanced specificity for the detection of tumor cells. The CellSearch System(®) can detect 1 CTC in 7.5 mL of peripheral blood, with high reproducibility. Its detection rate and accuracy for CTCs have been confirmed. In the United States, clinical trials have used this system to detect CTCs in patients with metastatic breast cancer, metastatic colorectal cancer, and metastatic prostate cancer, and CTCs have been confirmed to be a useful prognostic factor. This system was also suggested to be useful for monitoring treatment response in patients with metastatic breast cancer and was approved by the United States Food and Drug Administration in 2004. Measuring CTC counts can facilitate the early prediction of treatment response and thereby avoid unnecessary therapy. CTCs may also be a useful biomarker for molecular targeted agents, enabling the identification of patients most likely to respond to a given treatment and facilitating treatment selection. However, the widespread use of CTC monitoring as a routine examination requires a further improvement in measurement sensitivity, the establishment of criteria for quantitative and qualitative evaluations, and additional clear-cut evidence supporting the clinical significance of CTCs. We expect that CTCs will be established to be a new diagnostic and therapeutic index for breast cancer.


Anti-cancer Agents in Medicinal Chemistry | 2012

Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors

Youngjin Park; Ayako Moriyama; Tomoaki Kitahara; Yutaka Yoshida; Tasuku Urita; Ryoji Kato

Recent gene profiling studies have identified at least 5 major subtypes of breast cancer, including normal type, luminal A type, luminal B type, human epidermal growth factor receptor (HER)-2 positive type, and basal-like type. Triple-negative breast cancer (TNBC), showing no or low expressions of estrogen receptor (ER), progesterone receptor (PgR), and HER2, considered important clinical biomarkers, accounts for 10% to 20% of all breast cancers. Hormonal therapy and molecular targeted therapy are not indicated for the management of TNBC, resulting in poor outcomes. Because TNBC lacks clear-cut therapeutic targets, effective treatment strategies remain to be established. However, TNBC is known to share similar biologic characteristics with basal-like type breast cancer and is often accompanied by loss of functional BRCA, a gene-modifying enzyme. Breast cancer with BRCA1 or BRCA2 mutations is accompanied by activation of the enzyme poly(ADP-ribose) polymerase (PARP). PARP, a DNA base-excision repair enzyme, is known to play a central role in gene repair, along with BRCA. Because some breast cancers with BRCA1 or BRCA2 mutations are TNBC, the suppression of PARP has attracted attention as a new treatment strategy for TNBC. In this article, we review the clinical characteristics of TNBC, discuss problems in treatment, and briefly summarize the international development status of PARP inhibitors.


Ultrastructural Pathology | 2001

Unique Cellular Features in Atypical Adenomatous Hyperplasia of the Lung: Ultrastructural Evidence of Its Cytodifferentiation

Makoto Osanai; Tomofumi Igarashi; Yutaka Yoshida

Atypical adenomatous hyperplasia (AAH) of the lung could be a good material to understand the histogenesis of peripherally occurring, well-differentiated adenocarcinoma. However, its true biological significance remains to be clarified. The authors present the histomorphological studies of this lesion and compare the ultrastructure with that of nonmucinous bronchioloalveolar carcinoma (BAC) to define characteristic features of AAH. Light microscopy showed the well-preserved pulmonary architecture, proliferated neoplastic cells without marked cellular atypia, and no transitional area to obvious adenocarcinoma. Intranuclear inclusion was present in a large number of neoplastic cells. Electron microscopy revealed that cuboidal or low columnar neoplastic cells proliferated actively but were not crowded on slightly thickened fibrous alveolar septa with both Clara-like granules and small lamellar bodies in the cytoplasm resembling that of Clara cell and type 2 pneumocyte. Some of the nuclei had characteristic invaginations of its nuclear membrane. Although the findings appear to be nonspecific for AAH, the authors emphasize that AAH is an alveolar intraepithelial neoplasia that represents a very early stage in the continuous developmental spectrum of adenomatous neoplasia in the bronchioloalveolar region corresponding to dysplasia or intraepithelial neoplasia in other organs, and will give the significance to speculate its histogenesis.


Surgery Today | 2010

Intersigmoid hernia: Report of a case

Yasuhiro Nihon-Yanagi; Mitsuru Ooshiro; Aisaku Osamura; Ryuichi Takagi; Ayako Moriyama; Tasuku Urita; Yutaka Yoshida; Hiroshi Tanaka; Yui Sugishita; Takashi Oshiro; Takahiro Kinoshita; Makoto Nagashima; Shinichi Okazumi

A 28-year-old man with no previous history of abdominal surgery presented at a local hospital with abdominal pain. He was diagnosed to have an intestinal obstruction and was treated conservatively. However, the symptoms persisted, and he was thereafter referred to this hospital. Plain abdominal radiographs demonstrated small-bowel gas. A computed tomographic scan of the abdomen disclosed wall thickening of an edematous, fluid-filled ileum. An exploratory laparotomy was performed to determine the cause of the intestinal obstruction. The ileum had herniated into the intersigmoid fossa, 100 cm proximal to the ileocecal valve, and the patient was diagnosed to have an intersigmoid hernia. Since the incarcerated portion of the small bowel was viable, reduction of the hernia and closure of the defect in the sigmoid mesocolon were performed. The postoperative course was uneventful. A sigmoid mesocolon hernia is an uncommon condition. This report presents a case of intersigmoid hernia and a review of 60 cases of sigmoid mesocolon hernia reported in Japan.


Case Reports in Gastroenterology | 2013

Tumor-like growth of giant inflammatory polyposis in a patient with ulcerative colitis.

Makoto Nagashima; Yui Sugishita; Ayako Moriyama; Mitsuru Ooshiro; Kengo Kadoya; Ayami Sato; Tomoaki Kitahara; Ryuichi Takagi; Tasuku Urita; Yutaka Yoshida; Hiroshi Tanaka; Takashi Oshiro; Kentaro Nakamura; Yasuo Suzuki; Nobuyuki Hiruta; Shinichi Okazumi; Ryoji Katoh

We report a unique case of giant obstructing inflammatory polyposis associated with ulcerative colitis (UC). A 25-year-old Japanese man with an UC history of 2 years and 6 months was referred to our institution because of diarrhea and melena. His computed tomography scan showed marked dilation of the transverse and descending colon; therefore, we performed total colectomy. Macroscopic evaluation of the excised specimen indicated constricting lesions with giant polyposis in the transverse and descending colon. The polyposis consisted of narrow worm- or noodle-like polyps that bridged over the irregular ulcers. Histologic evaluation of the excised specimen indicated transmural inflammation with a thickened proper muscular layer overlaid with inflammatory polyposis. Based on these data, a diagnosis of giant inflammatory polyposis should be considered in patients who have had UC. Although giant inflammatory polyposis is considered benign, surgical treatment may be indicated to avoid serious complications.


Pediatrics International | 1997

Acute fulminant ulcerative colitis with toxic megacolon.

Chiharu Igarashi; Tsukasa Hori; Masaki Yoshida; Masato Yokozawa; Shigeru Fujita; Kazuhiko Yonezawa; Matsumi Tosaka; Yutaka Yoshida

An 11‐year‐old boy with acute fulminant ulcerative colitis (UC) is presented. He had systemic deterioration with frequent diarrhea and lethargy. Acute fulminant UC associated with toxic megacolon was diagnosed by rectal endoscopy and biopsied specimen. He was treated with intensive intravenous administration of prednisolone and total parenteral nutrition. He recovered completely without any surgical intervention.


World Journal of Gastrointestinal Surgery | 2010

Sporadic gastric carcinoid tumor successfully treated by two-stage laparoscopic surgery: A case report.

Takahiro Kinoshita; Takashi Oshiro; Tasuku Urita; Yutaka Yoshida; Mitsuru Ooshiro; Shinichi Okazumi; Ryoji Katoh; Daisuke Sasai; Nobuyuki Hiruta

We report a case of sporadic gastric carcinoid tumor successfully treated by two-stage laparoscopic surgery. A 38-year old asymptomatic woman was referred to our hospital for evaluation of a submucosal tumor of the stomach. Endoscopic examination showed a solitary submucosal tumor without ulceration or central depression on the posterior wall of the antrum and biopsy specimens were not sufficient to determine the diagnosis. Endoscopic ultrasound revealed a tumor nearly 2 cm in diameter arising from the muscle layer and a computed tomography scan showed the tumor enhanced in the arterial phase. Laparoscopic wedge resection was performed for definitive diagnosis. Pathologically, the tumor was shown to be gastric carcinoid infiltrating the muscle layer which indicated the probability of lymph node metastasis. Serum gastrin levels were normal. As a radical treatment, laparoscopy-assisted distal gastrectomy with regional lymphadenectomy was performed 3 wk after the initial surgery. Finally, pathological examination revealed no lymph node metastasis.


Journal of Infection and Chemotherapy | 2008

Fournier's gangrene progressing from the buttocks to the scrotum following a perianal abscess

Yui Sugishita; Makoto Nagashima; Mitsuru Ooshiro; Tasuku Urita; Ayako Moriyama; Yutaka Yoshida; Hiroshi Tanaka; Yasuhiro Nihon-Yanagi; Kazuki Koide; Miyoji Wakabayashi; Tetsuro Ueda; Muneyuki Yamaguchi; Ryoji Katoh

We describe a case of gas-producing infection following a perianal abscess. A 61-year-old man was admitted to our hospital complaining of perineal pain and was found to have a perianal abscess. He was diabetic but had not received treatment for the disease. Although the perianal abscess was drained and antibiotic treatment started, severe swelling of the scrotum, with crepitation, redness, and partial necrosis progressed rapidly. Computed tomography revealed subcutaneous gas formation in the scrotum. A culture study revealed Clostridium, Enterococcus, and numerous other types of bacteria. The patient was diagnosed with Fournier’s gangrene caused by infection with Clostridium in combination with other species of bacteria. The infection was refractory to drainage and antibiotic therapy. Thus, repeated extensive debridement of all necrotic tissue in the scrotum was required until healthy granulation was present in the wound. Our case shows that, in patients with Fournier’s gangrene caused by infection with Clostridium in combination with other species of bacteria, the mainstay of treatment should be open drainage and aggressive surgical debridement of all necrotic tissue, followed by broadspectrum antibiotic therapy.


Journal of Clinical Oncology | 2014

Efficacy and tolerability of oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of folfox therapy in colorectal cancer patients.

Makoto Nagashima; Mitsuru Ooshiro; Ayako Moriyama; Kengo Kadoya; Ayami Sato; Tomoaki Kitahara; Ryuichi Takagi; Tasuku Urita; Yutaka Yoshida; Hiroshi Tanaka; Takashi Oshiro; Shinichi Okazumi; Ryoji Katoh

196 Background: The oxaliplatin-based regimen FOLFOX is widely used to treat patients with advanced colorectal cancer (CRC). However, dose-limiting toxicity after continuous oxaliplatin administration can lead to peripheral neuropathy. Several agents, including opioids, that have been employed to treat oxaliplatin-induced peripheral neuropathy (OIPN) have been examined in clinical settings regarding their protective and therapeutic effects. However, the pharmacotherapy of these agents has not yet been established. Therefore, we investigated the efficacy and tolerability of oxycodone for OIPN and subsequently with FOLFOX therapy in CRC patients. METHODS This was a single-center retrospective study of 64 CRC patients who underwent FOLFOX therapy at the Toho University Sakura Medical Center (Sakura, Japan). Controlled-release (CR) oxycodone was concomitantly administered to 29 patients (OXY group), whereas the additional 35 patients (non-OXY group) were not given oxycodone during the FOLFOX treatment course. The incidence and severity of OIPN and the number of FOLFOX cycles were measured and compared between the two groups. Neurological toxicities were assessed according to the Common Terminology Criteria for Advanced Events, version 3.0. RESULTS All study patients had OIPN. Most patients experienced grade 1 or 2 sensory neuropathy. Grade 3 sensory neuropathy was observed in two patients in the non-OXY group. All patients in the OXY group completed the scheduled FOLFOX therapy, whereas FOLFOX therapy was discontinued in ten patients in the non-OXY group due to severe peripheral neuropathy. The median numbers of FOLFOX cycles in the OXY and non-OXY groups were 13 (range, 6-46) and 7 (range, 2-18), respectively (P < 0.05). The median cumulative oxaliplatin doses were 1072.3 mg/m2 (range, 408.7-3385.3 mg/m2) in the OXY group and 483.0 mg/m2 (range 76.2-1414.1 mg/m2) in the non-OXY group (P < 0.05). CONCLUSIONS Our findings indicate that CR oxycodone might attenuate the severity of OIPN and extend the use of FOLFOX therapy.


The Journal of the Japanese Society of Clinical Cytology | 1991

A case of mucinous cystadenocarcinoma of the pancreas diagnosed by aspiration cytology.

Reiko Kitamura; Katsuhiko Nakano; Takayuki Koseki; Yutaka Yoshida; Hirotoshi Tobioka; Hiroshi Harada; Toshimori Seki; Akihisa Wakayama; Makoto Kawabata

穿刺吸引細胞診によって術前診断が可能であった膵尾部原発の粘液性嚢胞腺癌の1例を経験したので報告する.症例は56歳, 女性.左上腹部腫瘤を主訴として来院し, 外傷の既往, 画像所見から臨床的には外傷性尿腫が疑われたが, 穿刺吸引細胞診では多量の粘液を背景とした高円柱状細胞の集塊に混在して, より異型の高度な腺癌細胞を認め, 粘液性嚢胞腺癌と診断された.その原発臓器については腫瘍の存在部位と推定組織型を勘案して, 膵臓が最も疑われた。摘出された腫瘍は, 肉眼的に膵尾部に連続して存在する多房性嚢胞性腫瘍で, 組織学的には大部分は異型に乏しい粘液性嚢胞腺腫の像で, その一部に乳頭状増殖の著しい粘液性嚢胞腺癌の成分を混在していた.すなわち, 細胞診における良性集塊と悪性集塊の混在性はこれを反映しているものと考えられた.本症例では, 穿刺吸引細胞診によって腫瘍の悪性度, 組織型のみならず, 原発臓器の推定も可能であった.これは腫瘍の臨床診断における細胞診の有用性を示すものといえよう.

Collaboration


Dive into the Yutaka Yoshida's collaboration.

Top Co-Authors

Avatar

Hiroshi Tanaka

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomofumi Igarashi

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuhiko Yonezawa

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar

Shosaku Abe

Sapporo Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge